1228 Stock Overview
A biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
CANbridge Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.21 |
| 52 Week High | HK$1.17 |
| 52 Week Low | HK$0.19 |
| Beta | -0.52 |
| 11 Month Change | -40.57% |
| 3 Month Change | -18.43% |
| 1 Year Change | -81.91% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -97.66% |
Recent News & Updates
CANbridge Pharmaceuticals Inc. (HKG:1228) Not Doing Enough For Some Investors As Its Shares Slump 28%
Nov 14
CANbridge Pharmaceuticals Inc. (HKG:1228) Stock Catapults 31% Though Its Price And Business Still Lag The Industry
Sep 27Lacklustre Performance Is Driving CANbridge Pharmaceuticals Inc.'s (HKG:1228) 28% Price Drop
Aug 07Recent updates
CANbridge Pharmaceuticals Inc. (HKG:1228) Not Doing Enough For Some Investors As Its Shares Slump 28%
Nov 14CANbridge Pharmaceuticals Inc. (HKG:1228) Stock Catapults 31% Though Its Price And Business Still Lag The Industry
Sep 27Lacklustre Performance Is Driving CANbridge Pharmaceuticals Inc.'s (HKG:1228) 28% Price Drop
Aug 07CANbridge Pharmaceuticals Inc.'s (HKG:1228) Share Price Boosted 56% But Its Business Prospects Need A Lift Too
Apr 23CANbridge Pharmaceuticals Inc.'s (HKG:1228) 26% Dip In Price Shows Sentiment Is Matching Earnings
May 05Shareholder Returns
| 1228 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -15.1% | -4.8% | -5.3% |
| 1Y | -81.9% | -14.6% | 11.3% |
Return vs Industry: 1228 underperformed the Hong Kong Biotechs industry which returned -14.6% over the past year.
Return vs Market: 1228 underperformed the Hong Kong Market which returned 11.3% over the past year.
Price Volatility
| 1228 volatility | |
|---|---|
| 1228 Average Weekly Movement | 20.7% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in HK Market | 19.1% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 1228's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1228's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 93 | James Qun Xue | www.canbridgepharma.com |
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Livmarli, an oral, minimally-absorbed, reversible IBAT inhibitor for the treatment of alagille syndrome and progressive familial intrahepatic cholestasis. It also engages in the development of CAN008, a CD95-Fc fusion protein that is in Phase 2/3 clinical trial for the treatment of glioblastoma multiforme; CAN106, an anti-C5 mAb that has completed Phase I clinical trial for paroxysmal nocturnal hemoglobinuria; and CAN103, a recombinant human enzyme replacement therapy (ERT) that is in Phase 2/3 clinical trials for gaucher disease.
CANbridge Pharmaceuticals Inc. Fundamentals Summary
| 1228 fundamental statistics | |
|---|---|
| Market cap | HK$89.22m |
| Earnings (TTM) | -HK$439.32m |
| Revenue (TTM) | HK$112.66m |
0.8x
P/S Ratio-0.2x
P/E RatioIs 1228 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1228 income statement (TTM) | |
|---|---|
| Revenue | CN¥104.61m |
| Cost of Revenue | CN¥37.69m |
| Gross Profit | CN¥66.92m |
| Other Expenses | CN¥474.87m |
| Earnings | -CN¥407.94m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.96 |
| Gross Margin | 63.97% |
| Net Profit Margin | -389.95% |
| Debt/Equity Ratio | -16.3% |
How did 1228 perform over the long term?
See historical performance and comparison